|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AC19
|
|
gptkbp:contraindication
|
active infection
hypersensitivity to satralizumab
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for injection
pre-filled syringe
|
|
gptkbp:genericName
|
gptkb:satralizumab
|
|
gptkbp:halfLife
|
30 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Enspryng
|
|
gptkbp:indication
|
gptkb:neuromyelitis_optica_spectrum_disorder
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:marketedAs
|
gptkb:Genentech
|
|
gptkbp:mechanismOfAction
|
interleukin-6 receptor antagonist
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site reaction
rash
arthralgia
|
|
gptkbp:target
|
gptkb:IL-6_receptor
|
|
gptkbp:bfsParent
|
gptkb:F._Hoffmann-La_Roche_AG
gptkb:Hoffmann-La_Roche
|
|
gptkbp:bfsLayer
|
7
|